immatics biotechnologies GmbH Obtains Important U.S. and European Patents  
7/14/2008 11:38:03 AM

TUEBINGEN, Germany, July 14, 2008 – immatics biotechnologies GmbH today announced that the company has obtained European patent protection for its technology platform XPRESIDENT™. In addition, the company has been granted important U.S. and European patents covering compounds contained in its lead product candidates IMA901 and IMA910.